0001564590-15-010594 Sample Contracts

AMENDMENT NO. 23 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT
Development and Clinical Supply Agreement • November 12th, 2015 • Fibrogen Inc • Pharmaceutical preparations

This AMENDMENT No. 23 (the “Twenty-third Amendment”), effective as of September 01, 2015 (the “Twenty-Third Amendment Effective Date”) by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer lngelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2012

AutoNDA by SimpleDocs
AMENDMENT NO.19 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT
Development and Clinical Supply Agreement • November 12th, 2015 • Fibrogen Inc • Pharmaceutical preparations

THIS AMENDMENT No. 19 (the “Nineteenth Amendment”), effective as of March 01, 2015 (the “Nineteenth Amendment Effective Date”) by and between Boehringer Ingelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 05, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 20

AMENDMENT NO. 18 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT
Clinical Supply Agreement • November 12th, 2015 • Fibrogen Inc • Pharmaceutical preparations

THIS AMENDMENT No. 18 (the “Eighteenth Amendment”), effective as of February 15, 2015 (the “Eighteenth Amendment Effective Date”) by and between Boehringer lngelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 05, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10,

AMENDMENT NO. 16 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT
Development and Clinical Supply Agreement • November 12th, 2015 • Fibrogen Inc • Pharmaceutical preparations

THIS AMENDMENT No. 16 (the “Sixteenth Amendment”), effective as of December 08, 2014 (the “Sixteenth Amendment Effective Date”) by and between BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH, Binger Str. 173, 55216 Ingelheim, German y (“BI”) and FIBROGEN, INC., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement originally entered into by and between BOEHRINGER INGELHEIM PHARMA GMBH & Co. KG , Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1 , effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No . 4, effective as of January 24, 2011 , Amendment No. 5, effective as of Apri1 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January I , 2012, Amendment No. 8, effective a

AMENDMENT NO. 20 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT
Development and Clinical Supply Agreement • November 12th, 2015 • Fibrogen Inc • Pharmaceutical preparations

THIS AMENDMENT No. 20 (the “Twentieth Amendment”), effective as of June 01, 2015 (the “Twentieth Amendment Effective Date”) by and between Boehringer lngelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 Ingelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (''FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer Ingelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1 , effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011 , Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 201 I , Amendment No. 7, effective as of January 01, 2012, Amendment No. 8, effective as of July 10, 2

AMENDMENT NO. 15 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT
Development and Clinical Supply Agreement • November 12th, 2015 • Fibrogen Inc • Pharmaceutical preparations

THIS AMENDMENT No. 15 (the “Fifteenth Amendment “), effective as of October 20, 2014 (the “Fifteenth Amendment Effective Date”) by and between Boehringer lngelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 lngelheim, Germany (“BI'') and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer lngelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011,

AMENDMENT NO. 21 TO THE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT
Development and Clinical Supply Agreement • November 12th, 2015 • Fibrogen Inc • Pharmaceutical preparations

This AMENDMENT No. 21 (the “Twenty-first Amendment”), effective as of May 29, 2015 (the “Twenty­ first Amendment Effective Date”) by and between Boehringer lngelheim Biopharmaceuticals GmbH, Binger Str. 173, 55216 lngelheim, Germany (“BI”) and FibroGen, Inc., 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between Boehringer lngelheim Pharma GmbH & Co. KG, Birkendorfer Str. 65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FibroGen on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No. 4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 201 l, Amendment No. 7, effective as of January 01 , 2012, Amendment No. 8, effective as of July 10

AMENDMENT NO.17 TOTHE PROCESS DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT
Development and Clinical Supply Agreement • November 12th, 2015 • Fibrogen Inc • Pharmaceutical preparations

THIS AMENDMENT No. 17 (the “Seventeenth Amendment”), effective as of December 08, 2014 (the “Seventeenth Amendment Effective Date”) by and between BOEHRINGER INGELHEIM BIOPHARMACEUTICALS GMBH, Binger Str. 173, 55216 lngelheim, Germany (“'BI”) and FIBROGEN, INC. 409 Illinois Street, San Francisco, CA 94158, USA (“FibroGen”), amends the Process Development and Clinical Supply Agreement entered into by and between BOEHRINGER INGELHEIM PHARMA GMBH & Co. KG, Birkendorfer Str.65, 88397 Biberach an der Riss, Germany (“BI Pharma”) and FIBROGEN on November 29, 2007, as amended pursuant to the letter agreements entered into as of June 26, 2008 and August 18, 2008, Amendment No. 1, effective as of May 28, 2009, Amendment No. 3, effective as of November 5, 2010, Amendment No.4, effective as of January 24, 2011, Amendment No. 5, effective as of April 15, 2011, Amendment No. 6, effective as of May 26, 2011, Amendment No. 7, effective as of January 1, 2012, Amendment No. 8, effective as of July 10, 2

Time is Money Join Law Insider Premium to draft better contracts faster.